Abstract:Puerarin is a potential therapeutic agent for cardiovascular diseases. But its poor oral bioavailability restricts Its clinical application. In present study, as an evaluation of a formulation to improve the bioavailability of the drug, puerarin and its phospholipid complex were given to rats by intragastrically (i.g.) administration to compare pharmacokinetic, tissue distribution, and excretion. Serum samples were obtained at designated times after a single oral dose of 400 mg/kg puerarin or its complex. Tissue samples (heart, liver, spleen, kidney, lung, and brain), urine, and feces were collected and analyzed by a sensitive and specific high. performance liquid chromatography (HPLC) method after i.g. administration of puerarin or its phospholipid complex. Compartmental and non-compartmental analyses were applied to the serum concentration versus time data. Pharmacokinetic parameters were calculated using the 3P97 pharmacokinetic software package. An open two-compartment, first-order model was selected for pharmacokinetic modeling. The results showed that after i.g. administration of 400 mg/kg puerarin and its phospholipid complex (equivalent to 400 mg/kg of puerarin), the pharmacokinetic parameters of the two formulations were different. The serum concentrations reached peaks at 0.894 +/- 0.521 h and 0.435 +/- 0.261 h, respectively, indicating the complex was more readily absorbed in serum than puerarin. The maximum concentrations for puerarin and its complex were 1.367 +/- 0.586 mg.L-1 and 2.202 +/- 1.28 mg.L-1 and AUC were 5.779 +/- 1.662 mg.h. L-1 and 8.456 +/- 0.44 mg.h L-1, respectively, indicating a higher bioavailability for the complex. The widely distribution characteristics of puerarin and its complex in tissues post-i.g. administration was identical and in a descending order as follows: lung, kidney, liver, heart, spleen, and brain. However, the amount was different. Puerarin distribution was higher in heart, lung, and brain after administering the complex. The cumulative 72 h urinary excretion of puerarin after i.g. administration of puerarin and its complex accounted for 1.05%, 1.11% of the administered dose, respectively. The cumulative feces excretion of puerarin was 32.3% and 25.5%. To sum up, oral administration of puerarin phospholipid complex modified the pharmacokinetics and tissue distribution of puerarin and it could be an effective oral formulation for puerarin.

Enhanced Oral Bioavailability of Acetylpuerarin by Poly(lactide-Co-glycolide) Nanoparticles Optimized Using Uniform Design Combined with Response Surface Methodology

Polysorbate 80‐coated PLGA nanoparticles improve the permeability of acetylpuerarin and enhance its brain‐protective effects in rats

Preparation and Evaluation of Puerarin-loaded PLGA Nanoparticles for Improving Oral Bioavailability in SD Rats

Enhanced Oral Absorption and Therapeutic Effect of Acetylpuerarin Based on D-Alpha-Tocopheryl Polyethylene Glycol 1000 Succinate Nanoemulsions

Glycyrrhizic Acid-Phospholipid Complex: Preparation Process Optimization and Therapeutic and Pharmacokinetic Evaluation in Rats

Enhancement of Oral Bioavailability of Puerarin by Polybutylcyanoacrylate Nanoparticles

Oral Delivery of Decanoic Acid Conjugated Plant Protein Shell Incorporating Hybrid Nanosystem Leverage Intestinal Absorption of Polyphenols.

Oral Delivery of Puerarin Nanocrystals to Improve Brain Accumulation and Anti-Parkinsonian Efficacy.

Enhanced Bioavailability of Apigenin Via Preparation of a Carbon Nanopowder Solid Dispersion.

In vitro evaluation and in situ intestinal absorption characterisation of paeoniflorin nanoparticles in a rat model

Poly(lactic-co-glycolic) acid nanoparticles improve oral bioavailability of hypocrellin A in rat

Preparation, characterization and bioavailability of oral puerarin nanoparticles by emulsion solvent evaporation method

Enhancement of the Bioavailability of a Novel Anticancer Compound (acetyltanshinone IIA) by Encapsulation Within Mpeg-Plga Nanoparticles: a Study of Formulation Optimization, Toxicity, and Pharmacokinetics

Nanoparticles Mediating the Sustained Puerarin Release Facilitate Improved Brain Delivery to Treat Parkinson's Disease

PLGA Nanoparticles Improve the Oral Bioavailability of Curcumin in Rats: Characterizations and Mechanisms.

The Comparison of Different Daidzein-Plga Nanoparticles in Increasing Its Oral Bioavailability

Improved Solubility and Oral Bioavailability of Apigenin Via Soluplus/Pluronic F127 Binary Mixed Micelles System

PLGA Nanoparticles for the Oral Delivery of Nuciferine: Preparation, Physicochemical Characterization and in Vitro/in Vivo Studies

Puerarin Loaded PLGA Nanoparticles: Optimization Processes of Preparation and Anti-alcohol Intoxication Effects in Mice

Pharmacokinetic, Tissue Distribution, and Excretion of Puerarin and Puerarin-Phospholipid Complex in Rats

Studies on Pharmacy Characters and Pharmacokinetics of Oral Apigenin Loaded Solid Lipid Nanoparticle